Show simple item record

dc.contributor.authorLasa Elgarresta, Jaione
dc.contributor.authorMosqueira Martín, Laura
dc.contributor.authorNaldaiz Gastesi, Neia
dc.contributor.authorSáenz Peña, Amets
dc.contributor.authorLópez de Munain Arregui, Adolfo José
dc.contributor.authorVallejo Illarramendi, Ainara ORCID
dc.date.accessioned2020-01-10T11:47:12Z
dc.date.available2020-01-10T11:47:12Z
dc.date.issued2019-09-02
dc.identifier.citationInternational Journal Of Molecular Sciences 20(18) : (2019) // Article ID 4548es_ES
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10810/37572
dc.description.abstractLimb-girdle muscular dystrophy recessive 1 (LGMDR1), previously known as LGMD2A, is a rare disease caused by mutations in the CAPN3 gene. It is characterized by progressive weakness of shoulder, pelvic, and proximal limb muscles that usually appears in children and young adults and results in loss of ambulation within 20 years after disease onset in most patients. The pathophysiological mechanisms involved in LGMDR1 remain mostly unknown, and to date, there is no effective treatment for this disease. Here, we review clinical and experimental evidence suggesting that dysregulation of Ca2+ homeostasis in the skeletal muscle is a significant underlying event in this muscular dystrophy. We also review and discuss specific clinical features of LGMDR1, CAPN3 functions, novel putative targets for therapeutic strategies, and current approaches aiming to treat LGMDR1. These novel approaches may be clinically relevant not only for LGMDR1 but also for other muscular dystrophies with secondary calpainopathy or with abnormal Ca2+ homeostasis, such as LGMD2B/LGMDR2 or sporadic inclusion body myositis.es_ES
dc.description.sponsorshipThis research was funded by Instituto de Salud Carlos III, co-funded by European Regional Development Fund/European Social Fund, "Investing in your future" (A.V.-I., PI17/00676; A.L.d.M., PI17/01841); the Basque Government (A.V.-I., 2016111091) and Diputacion Foral de Gipuzkoa (A.V.-I., 2018-000117-01-B and 2019-00362-01-B). A.V.-I. holds a Ramon y Cajal contract funded by the Spanish Ministry of Economy and Competitiveness, and J.L.-E. holds a PhD fellowship from the Basque Government.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectcalpain 3es_ES
dc.subjectcalciumes_ES
dc.subjectLGMD2Aes_ES
dc.subjectLGMDR1es_ES
dc.subjectmuscular dystrophieses_ES
dc.subjectcalpainopathyes_ES
dc.subjectNF-kappa Bes_ES
dc.subjectpermeability transition porees_ES
dc.subjectmuscle-specific calpaines_ES
dc.subjectskeletal-musclees_ES
dc.subjectoxidative stresses_ES
dc.subjectin-vivoes_ES
dc.subjectsarcoplasmic-reticulumes_ES
dc.subjectmitochondrial activityes_ES
dc.subjectproteolytic activityes_ES
dc.subjectgenetic isolatees_ES
dc.titleCalcium Mechanisms in Limb-Girdle Muscular Dystrophy with CAPN3 Mutationses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Attribution 4.0 International (CC BY 4.0)es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/20/18/4548es_ES
dc.identifier.doi10.3390/ijms20184548
dc.departamentoesNeurocienciases_ES
dc.departamentoesPediatríaes_ES
dc.departamentoeuNeurozientziakes_ES
dc.departamentoeuPediatriaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Attribution 4.0 International (CC BY 4.0)